Breaking News: Helix TCS Inc. and BioTrackTHC Close Previously Announced Merger

Helix TCS, Inc. (OTCQB: HLIX), in conjunction with its strategic capital partner, Rose Capital, is pleased to announce the closing of its previously reported merger with Bio-Tech Medical Software, Inc. dba BioTrackTHC.  The merger closed on June 1st.  Zachary L. Venegas will continue as the CEO of Helix TCS, Inc., and is to assume the role of Executive Chairman for the combined company. As previously announced, Patrick Vo will continue as CEO of BioTrack.

“The closing of this merger is a landmark event for Helix and BioTrack from a strategic and operational perspective. As a combined company, we are unique in the industry in serving virtually every segment of the market – whether it is compliance software through BioTrack, the wholesale marketplace through Cannabase, security, transport, or cash services through Helix, or the advisory that we can provide customers due to our data infrastructure.  We continue to support our clients in whatever challenges they face in becoming safer, stronger, and more profitable, whether they operate in the U.S. or internationally.  At the same time, investors will see margin improvement as reporting and administrative costs are spread across a much larger revenue base and costs are rationalized.

“As a combined company with $12MM in 2017 revenue, we will continue to generate greater value for clients and shareholders. Helix’s unrelenting focus on strategy and disciplined execution will allow Biotrack to further harness the spirit that made it a market pioneer, with significant market share in government, dispensary, and grow segments of the seed to sale market, and translate that spirit into renewed technological innovation and leadership.

“This transaction represents the next step in our evolution as a market leader.  It is also another milestone achieved by using our team’s deep experience in strategy, entrepreneurship, M&A, and frontier markets to build a world-class company.” stated Mr. Venegas.

Venegas further added: “We are very excited to move ahead, and we would like to thank Rose Capital, who shared our vision and had the fortitude to finance the transaction, as well as the team at BioTrack, who have been stalwart partners throughout this transformational deal.”

“BioTrackTHC celebrates a historic milestone today as we formally join the Helix family,” said Patrick Vo, CEO of BioTrackTHC. “By merging with our highly regarded peer, under the Helix umbrella, we will be able to significantly increase our ability to deliver outstanding technology, capabilities and service to the cannabis industry while drawing on Helix’s proven track record of fostering meaningful, strategic partnerships. The future has never looked brighter and we look forward to collaborating with Helix to embrace the exciting new challenges ahead.”

 

Sponsored Content Release. Click for Full Disclosure

 

Leave a Comment